2.29

2.97% -0.07

Dogwood Therapeutics Inc (DWTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$2.36

Offen:

$2.37

24-Stunden-Volumen:

70,165

Relative Volume:

1.10

Marktkapitalisierung:

$77.84M

Einnahmen:

Nettoeinkommen (Verlust:

$-28.32M

KGV:

-0.216

EPS:

-10.6039

Netto-Cashflow:

$-15.52M

1W Leistung:

-13.58%

1M Leistung:

+27.93%

6M Leistung:

-25.89%

1J Leistung:

-54.20%

1-Tages-Spanne:

$2.2509

$2.38

1-Wochen-Bereich:

$2.2509

$2.74

52-Wochen-Spanne:

$1.28

$9.50

Dogwood Therapeutics Inc Stock (DWTX) Company Profile

Firmenname

Dogwood Therapeutics Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(866) 620-8655

Adresse

44 MILTON AVENUE, ALPHARETTA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-12

Neueste SEC-Einreichungen

DWTX's Discussions on Twitter

Compare DWTX vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DWTX Dogwood Therapeutics Inc	2.29	79.20M	0	-28.32M	-15.52M	-10.60
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten

Aug 21, 2026

Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest SessionImpulse Wave - vinanet.vn

Aug 21, 2026

Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - Kalkine

Aug 21, 2026

Aug 20, 2026

Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus

Aug 20, 2026

Aug 19, 2026

Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn

Aug 19, 2026

Aug 18, 2026

Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat

Aug 18, 2026

Aug 17, 2026

Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times

Aug 17, 2026

Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan

Aug 17, 2026

What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat

Aug 17, 2026

Aug 14, 2026

Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView

Aug 14, 2026

Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan

Aug 14, 2026

Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan

Aug 14, 2026

Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo

Aug 14, 2026

Aug 13, 2026

Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat

Aug 13, 2026

Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView

Aug 13, 2026

DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView

Aug 13, 2026

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times

Aug 13, 2026

Aug 11, 2026

Dogwood Therapeutics (DWTX) Rises 2.78% as Buyers Defend Key $1.76 SupportMAMA Signal - vinanet.vn

Aug 11, 2026

Aug 10, 2026